News Update

Feb 01, 2002
Pharmaceutical Executive
Washington, DC-A new advisory committee appointed by HHS secretary Tommy Thompson will scrutinize agency policies to identify ways to improve programs and regulations.
Feb 01, 2002
Pharmaceutical Executive
Geneva-The pharma industry has given a guarded welcome to a World Health Organization report that explicitly links poverty and poor health.
Feb 01, 2002
Pharmaceutical Executive
Washington DC-Abbott Labs and Bayer made Multinational Monitor's 2001 list of the ten worst corporations. The Washington-based magazine was founded by consumer activist and one-time US presidential hopeful Ralph Nader.
Feb 01, 2002
Pharmaceutical Executive
Washington, DC-Pro-life advocates recently dropped a lawsuit challenging the promotion of abortifacient RU-486 through ads sponsored by the National Abortion Federation. The suit charged NAF with using deceptive advertising by promoting Mifepristone as safe in several national magazines, including Self, Cosmopolitan, InStyle, Vanity Fair, and People. The ads stated, "You have the freedom to choose. And now, you have another safe abortion choice."
Feb 01, 2002
Pharmaceutical Executive
In July, after a wide-ranging review of pharmaceutical legislation, the EC determined that the current ban on direct-to- consumer advertising should be balanced by a pilot system aimed to "ensure the availability of better, clear, and reliable information on authorized pharmaceuticals." It said the pilot should apply to diabetes, AIDS, and asthma products, citing the strong public demand for such information and the ease of monitoring the results of a five-year pilot study for those products.
Jan 01, 2002
Pharmaceutical Executive
Once thought to be a disease of the past, tuberculosis is now a front burner health problem.
Jan 01, 2002
Pharmaceutical Executive
The wrangling over whether pharma companies invest more in R&D than in marketing is heating up again.
Jan 01, 2002
Pharmaceutical Executive
Medical experts around the world warn that inappropriate use of Cipro (ciproflaxin) is only one aspect of the growing problem of bacterial resistance to treatment.
Jan 01, 2002
Pharmaceutical Executive
MICHIGAN-In an aggressive move to squeeze price discounts from the industry, Michigan recently released a list of pharmaceuticals, mostly generic and lower-priced,
Jan 01, 2002
Pharmaceutical Executive
For once, health activists and the pharma industry both welcomed a World Trade Organization declaration on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and public health, but there is little doubt that it opens the way to further compulsory licensing and parallel imports.
native1_300x100
lorem ipsum